Gland Pharma quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	1,800	1,506	+19.6%
EBITDA	489	368	+33.1%
EBITDA margin	27.2%	24.4%	+2.8 pts
Profit before tax	435	313	+39.1%
Net profit	317	215	+47.1%
EPS	₹19.23	₹13.08	+47.0%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	1,800	1,743	1,695	1,487	1,506	1,425	1,384	1,406	1,402	1,537	1,545	1,373	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	61.2	111	63.2	84.2	57.5	44.0	58.5	59.7	51.4	42.1	37.4	53.2
	1,861	1,854	1,759	1,571	1,563	1,469	1,443	1,465	1,453	1,580	1,583	1,427
	588	594	530	558	557	588	437	486	462	575	464	518
	1.9	2.3	1.5	1.9	0.9	3.1	2.1	2.7	6.6	6.8	6.4	6.1
	34.2	−5.0	45.3	−6.6	−37.1	−103	23.2	86.9	96.0	17.9	129	−2.5
	444	412	424	385	408	373	343	330	356	352	345	305
	4.4	10.0	3.9	7.8	11.5	7.5	22.8	6.1	5.6	10.0	5.3	6.0
	111	109	108	106	101	95.8	96.3	93.8	92.0	92.6	105	81.3
	243	227	260	234	209	216	219	204	218	228	244	223
	1,427	1,348	1,372	1,287	1,250	1,181	1,143	1,209	1,235	1,281	1,299	1,137
	489	513	435	314	368	348	360	297	264	359	356	324
	378	404	327	208	267	252	264	203	172	266	251	243
Profit
	435	506	386	284	313	288	299	257	218	298	283	290
	0.0	0.0	−24.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	435	506	362	284	313	288	299	257	218	298	283	290
	125	144	109	104	102	104	94.5	95.9	77.8	100	97.4	89.0
	−7.5	−4.9	−8.4	−3.6	−4.7	−1.9	0.1	−2.7	−3.3	5.6	−6.1	6.8
	118	139	101	100	97.3	102	94.6	93.2	74.5	106	91.3	95.8
	317	367	261	184	215	187	205	164	144	192	192	194
	317	367	261	184	215	187	205	164	144	192	192	194
	−26.7	101	40.8	103	186	64.5	−93.3	96.3	−12.2	−42.6	75.0	−15.6
	290	468	302	287	402	251	111	260	132	150	267	178
	317	367	261	184	215	187	205	164	144	192	192	194
Per share
	₹19.23	₹22.26	₹15.87	₹11.15	₹13.08	₹11.32	₹12.42	₹9.93	₹8.73	₹11.68	₹11.65	₹11.78
	₹19.22	₹22.23	₹15.87	₹11.15	₹13.08	₹11.32	₹12.42	₹9.93	₹8.73	₹11.68	₹11.65	₹11.78
Other comprehensive income — detail
	−26.7	101	40.8	103	186	64.5	—	—	—	—	—	—
	2.5	6.6	6.4	1.9	−1.3	−0.8	−2.2	2.1	−0.6	−0.5	−2.9	1.7
	0.6	3.1	0.1	0.5	−0.2	−0.2	—	—	—	—	—	—
	—	—	—	—	—	—	−0.6	0.5	−0.2	−0.7	0.0	0.2
	−28.6	97.4	34.4	101	188	—	−91.6	94.8	−11.7	—	77.9	—
	0.0	0.0	0.0	0.0	0.0	−65.2	—	—	—	—	—	—
	—	—	—	—	—	—	0.0	0.0	0.0	42.7	0.0	17.1
	290	468	302	287	402	251	111	260	132	150	267	178
Per share — as-filed variants
	₹19.23	₹22.26	₹15.87	₹11.15	₹13.08	₹11.32	₹12.42	₹9.93	₹8.73	₹11.68	₹11.65	₹11.78
	₹19.22	₹22.23	₹15.87	₹11.15	₹13.08	₹11.32	₹12.42	₹9.93	₹8.73	₹11.68	₹11.65	₹11.78
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,176	1,151	1,119	933	984	937	921	830	837	938	946	852
	65.3%	66.1%	66.0%	62.8%	65.4%	65.8%	66.6%	59.1%	59.7%	61.0%	61.2%	62.0%
Adjusted (ex-exceptional items) — derived
	435	506	386	284	313	288	299	257	218	298	283	290
	0.0	0.0	−24.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	317	367	279	184	215	187	205	164	144	192	192	194
	₹19.23	₹22.26	₹16.94	₹11.15	₹13.08	₹11.32	₹12.42	₹9.93	₹8.73	₹11.68	₹11.65	₹11.78

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLAND₹3,049.00

Gland Pharma Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDIVISLAB AUROPHARMA PPLPHARMA SYNGENE WOCKPHARMA ASTERDM COHANCE LALPATHLABMcap ₹50,235 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	1,373.4	1,545.2	1,537.5	1,401.7	1,405.8	1,384.1	1,424.9	1,505.6	1,486.9	1,695.4	1,742.8	1,800.3
Other Income	53.2	37.4	42.1	51.4	59.7	58.5	44.0	57.5	84.2	63.2	111.5	61.2
Total Income	1,426.6	1,582.5	1,579.6	1,453.1	1,465.5	1,442.5	1,468.9	1,563.1	1,571.0	1,758.5	1,854.3	1,861.5
Expenses
+ Cost of Materials Consumed	517.9	464.0	574.7	461.7	485.9	437.4	587.6	557.4	558.4	529.9	594.1	588.2
+ Purchases of Stock-in-Trade	6.1	6.4	6.8	6.6	2.7	2.1	3.1	0.9	1.9	1.5	2.3	1.9
+ Changes in Inventories	-2.5	128.9	17.9	96.0	86.9	23.2	-102.7	-37.1	-6.6	45.3	-5.0	34.2
+ Employee Benefit Expense	305.0	345.3	351.6	355.5	329.8	342.9	373.4	408.0	385.0	424.2	411.6	444.0
+ Finance Costs	6.0	5.3	10.0	5.6	6.1	22.8	7.5	11.5	7.8	3.9	10.0	4.4
+ Depreciation & Amortisation	81.3	105.3	92.6	92.0	93.8	96.3	95.8	101.1	106.3	107.6	108.7	111.3
+ Other Expenses	222.8	244.2	227.8	217.5	203.5	218.5	216.1	208.7	234.1	259.6	226.9	242.6
Total Expenses	1,136.7	1,299.4	1,281.4	1,234.9	1,208.7	1,143.2	1,180.6	1,250.4	1,287.1	1,372.1	1,348.5	1,426.5
EBITDA	324.1	356.4	358.7	264.4	297.1	360.0	347.5	367.8	313.9	434.9	513.0	489.4
EBIT	242.8	251.0	266.0	172.4	203.2	263.6	251.8	266.7	207.6	327.2	404.4	378.1
Profit
PBT before Exceptional Items	289.9	283.2	298.2	218.2	256.8	299.3	288.3	312.7	283.9	386.5	505.8	435.0
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-24.3	0.0	0.0
Pretax Income	289.9	283.2	298.2	218.2	256.8	299.3	288.3	312.7	283.9	362.1	505.8	435.0
+ Current Tax	89.0	97.4	100.2	77.8	95.9	94.5	103.7	102.0	103.8	109.1	144.0	125.5
+ Deferred Tax	6.8	-6.1	5.6	-3.3	-2.7	0.1	-1.9	-4.7	-3.6	-8.4	-4.9	-7.5
Tax Expense	95.8	91.3	105.8	74.5	93.2	94.6	101.8	97.3	100.2	100.7	139.1	118.0
Net Income	194.1	191.9	192.4	143.8	163.5	204.7	186.5	215.5	183.7	261.5	366.7	317.0
+ Net Income — Continuing Ops	194.1	191.9	192.4	143.8	163.5	204.7	186.5	215.5	183.7	261.5	366.7	317.0
+ Other Comprehensive Income	-15.6	75.0	-42.6	-12.2	96.3	-93.3	64.5	186.5	102.8	40.8	100.9	-26.7
Total Comprehensive Income	178.5	266.8	149.8	131.6	259.9	111.4	251.1	402.0	286.5	302.2	467.6	290.2
Net Income to Common	194.1	191.9	192.4	143.8	163.5	204.7	186.5	215.5	183.7	261.5	366.7	317.0
Per Share
Basic EPS	11.78	11.65	11.68	8.73	9.93	12.42	11.32	13.08	11.15	15.87	22.26	19.23
Diluted EPS	11.78	11.65	11.68	8.73	9.93	12.42	11.32	13.08	11.15	15.87	22.23	19.22
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	64.5	186.5	102.8	40.8	100.9	-26.7
+ Items NOT to be Reclassified to P&L	1.7	-2.9	-0.5	-0.6	2.1	-2.2	-0.8	-1.3	1.9	6.4	6.6	2.5
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.2	-0.2	0.5	0.1	3.1	0.6
+ Tax on Items NOT to be Reclassified — alt tag	0.2	0.0	-0.7	-0.2	0.5	-0.6	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	77.9	—	-11.7	94.8	-91.6	—	187.6	101.4	34.4	97.4	-28.6
+ Tax on Items to be Reclassified	—	—	—	—	—	—	-65.2	0.0	0.0	0.0	0.0	0.0
+ Tax on Items to be Reclassified — alt tag	17.1	0.0	42.7	0.0	0.0	0.0	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	178.5	266.8	149.8	131.6	259.9	111.4	251.1	402.0	286.5	302.2	467.6	290.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	11.78	11.65	11.68	8.73	9.93	12.42	11.32	13.08	11.15	15.87	22.26	19.23
Diluted EPS — Continuing Operations	11.78	11.65	11.68	8.73	9.93	12.42	11.32	13.08	11.15	15.87	22.23	19.22
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	851.9	945.9	938.1	837.5	830.4	921.3	937.0	984.5	933.1	1,118.7	1,151.5	1,175.9
Gross Margin %	62.02	61.22	61.01	59.75	59.07	66.57	65.76	65.39	62.75	65.99	66.07	65.32
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	289.9	283.2	298.2	218.2	256.8	299.3	288.3	312.7	283.9	386.5	505.8	435.0
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-24.3	0.0	0.0
Net Income Adj (tax-effected)	194.1	191.9	192.4	143.8	163.5	204.7	186.5	215.5	183.7	279.1	366.7	317.0
EPS Adj	11.78	11.65	11.68	8.73	9.93	12.42	11.32	13.08	11.15	16.94	22.26	19.23
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	16.5	16.5	16.5	16.5	16.5	16.5	16.5	16.5	16.5	16.5	16.5	16.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Gland Pharma Q2 FY27 results date

Gland Pharma (NSE: GLAND) will announce its Q2 FY27 results (July–September 2026) on Friday, 6 November 2026, according to the board-meeting notice it filed on 21 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹317 crore, up 47.1% from ₹215 crore in Q1 FY26 and down 13.6% from ₹367 crore in Q4 FY26. Revenue from operations was ₹1,800 crore, up 19.6% year on year and up 3.3% from the previous quarter.

Board-meeting notice filed: 21 October 2026
Q2 FY26 results (a year earlier): 3 November 2025
Q1 FY27 results (the latest): 10 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 6 November 2026Friday · notice filed 21 Oct
Q1 FY27 net profit: ₹317 Cr+47.1% vs Q1 FY26−13.6% vs Q4 FY26
Q1 FY27 revenue: ₹1,800 Cr+19.6% vs Q1 FY26+3.3% vs Q4 FY26
Q1 FY27 operating margin: 21.0%+3.3 pts vs Q1 FY26−2.2 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹184 CrRevenue ₹1,487 Cr
Q1 FY27 EPS (basic): ₹19.23

Questions

When will Gland Pharma announce its Q2 FY27 results?

On 6 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 21 October 2026). Last year it reported Q2 FY26 on 3 November 2025.

What will Gland Pharma's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹184 crore and revenue from operations ₹1,487 crore. The latest quarter, Q1 FY27, had a net profit of ₹317 crore and revenue of ₹1,800 crore.

What were Gland Pharma's Q1 FY27 results?

Consolidated net profit was ₹317 crore, up 47.1% from ₹215 crore in Q1 FY26 and down 13.6% from ₹367 crore in Q4 FY26. Revenue from operations was ₹1,800 crore, up 19.6% year on year and up 3.3% from the previous quarter.

How has Gland Pharma's profit changed over the last four quarters?

Net profit by quarter: ₹184 crore in Q2 FY26, ₹261 crore in Q3 FY26, ₹367 crore in Q4 FY26 and ₹317 crore in Q1 FY27. That is ₹1,129 crore over the four quarters, up 46.5% from ₹770 crore in the four quarters before. Revenue from operations: ₹1,487 crore, ₹1,695 crore, ₹1,743 crore and ₹1,800 crore.

What was Gland Pharma's net profit in FY26?

Consolidated net profit was ₹1,027 crore in FY26 (April 2025–March 2026), up 47.1% from ₹699 crore in FY25. It was ₹772 crore in FY24 and ₹781 crore in FY23: up 31.5% over three years, 9.6% a year on average.

What was Gland Pharma's revenue in FY26?

Revenue from operations was ₹6,431 crore in FY26 (April 2025–March 2026), up 14.5% from ₹5,617 crore in FY25. It was ₹5,665 crore in FY24 and ₹3,625 crore in FY23: up 77.4% over three years, 21.1% a year on average.

Where do these Gland Pharma figures come from?

From Gland Pharma's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.